Pipeline2020-02-13T18:35:23-05:00

Product Pipeline

EyePoint Pipeline
  1. Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to EyePoint.
  2. Excludes China, Hong Kong, Taiwan and Macau
Dexycu (dexamethasone injectable suspension) 9%
Learn More at dexycu.com
click here for full Prescribing Information

Please complete the form below to receive information on the availability of Dexycu.

Dexycu (dexamethasone injectable suspension) 9%
Learn More at yutiq.com
click here for full Prescribing Information

YUTIQ Physician Perspective

Click here to see additional YUTIQ videos

Yutiq® Shorter Duration for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.

DurasertTM Bioerodible TKI

Potential Indication: Wet AMD

EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.